The results of this meta-analysis showed that a combination of EGFR-TKIs plus anti-VEGFR- agents prolonged PFS and ORR in patients with advanced NSCLC but failed to significantly improve OS. This evidence concerns the gene KDR and non-small cell lung carcinoma.